Silo Wellness (XCNQ:SILO) FCF Margin % : 104.21% (As of Jul. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Silo Wellness FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Silo Wellness's Free Cash Flow for the three months ended in Jul. 2023 was C$0.10 Mil. Silo Wellness's Revenue for the three months ended in Jul. 2023 was C$0.10 Mil. Therefore, Silo Wellness's FCF Margin % for the quarter that ended in Jul. 2023 was 104.21%.

As of today, Silo Wellness's current FCF Yield % is -13.59%.

The historical rank and industry rank for Silo Wellness's FCF Margin % or its related term are showing as below:

XCNQ:SILO' s FCF Margin % Range Over the Past 10 Years
Min: -10162.5 Med: -3169.13 Max: -56.45
Current: -56.45

During the past 3 years, the highest FCF Margin % of Silo Wellness was -56.45%. The lowest was -10162.50%. And the median was -3169.13%.

XCNQ:SILO's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: -0.03 vs XCNQ:SILO: -56.45

Silo Wellness FCF Margin % Historical Data

The historical data trend for Silo Wellness's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silo Wellness FCF Margin % Chart

Silo Wellness Annual Data

Trend

Oct20

Oct21

Oct22

FCF Margin %

-10,162.50

-3,169.13

-156.30

Silo Wellness Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
FCF Margin %	Get a 7-Day Free Trial										-122.73	-241.35	57.58	-89.72	104.21

Competitive Comparison of Silo Wellness's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Silo Wellness's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silo Wellness's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Silo Wellness's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Silo Wellness's FCF Margin % falls into.

Silo Wellness FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Silo Wellness's FCF Margin for the fiscal year that ended in Oct. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Oct. 2022 )	/	Revenue (A: Oct. 2022 )
	=	-0.719	/	0.46
	=	-156.30 %

Silo Wellness's FCF Margin for the quarter that ended in Jul. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jul. 2023 )	/	Revenue (Q: Jul. 2023 )
	=	0.099	/	0.095
	=	104.21 %

Silo Wellness FCF Margin % Related Terms

Thank you for viewing the detailed overview of Silo Wellness's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silo Wellness (XCNQ:SILO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Silo Wellness Inc (XCNQ:SILO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Consumers Road, Suite 702, Toronto, ON, CAN, M2J 4R4

Website

https://www.silowellness.com

Silo Wellness Inc operates psychedelic clinics and develops legal functional mushroom consumer products. It is focused on health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion.

Executives

Michael Hartman

Director